Effects of MCI-186 (edaravone), a novel free radical scavenger, upon experimental atherosclerosis in apolipoprotein E-deficient mice

Circulation Journal

Volumn 70, Issue 9, 2006, Pages 1216-1219

  Okabe, Taka Aki ^a   Kishimoto, Chiharu ^a   Shimada, Kana ^a   Murayama, Toshinori ^a   Yokode, Masayuki ^a   Kita, Toru ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Free radical scavenger; Oxidative stress

Indexed keywords

NORPHENAZONE; SCAVENGER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOHISTOCHEMISTRY; LIPID DIET; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS;

ANIMALS; ANTIPYRINE; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; FREE RADICAL SCAVENGERS; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; TIME FACTORS;

EID: 33748653204     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.1216     Document Type: Article

References (24)

1. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
3. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest 1991; 64: 5-15.
4. Kawashiri MA, Higashikata T, Takata M, Katsuda S, Miwa K, Nohara A, et al. Type III hyperlipoproteinemia exaggerated by Sheehan's syndrome with advanced systemic atherosclerosis. Circ J 2005; 69: 746-751.
5. Nasuno A, Matsubara T, Hori T, Higuchi K, Tsuchida K, Mezaki T, et al. Acute pulmonary thromboembolism induced by prophylactic heparin use and a heparin-coated catheter: A case of heparin-induced thrombocytopenia and thrombosis syndrome. Circ J 2003; 67: 96-98.
6. Espinola-Klein C, Rupperecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002; 105: 15-21.
7. Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH, et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 2000; 20: 1536-1542.
8. Parthasarathy S, Santanam N, Ramachandran S, Meilhac O. Oxidants and antioxidants in atherogenesis: an appraisal. J Lipid Res 1999; 40: 2143-2157.
9. Bernal-Mizrachi C, Gates AC, Weng S, Imamura T, Knutsen RH, DeSantis P, et al. Vascular respiratory uncoupling increases blood pressure and atherosclerosis. Nature 2005; 435: 502-506.
10. Franzoni F, Ghiadoni L, Galetta F, Plantinga Y, Lubrano V, Huang Y, et al. Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men. Am J Hypertens 2005; 18: 510-516.
11. Watanabe K, Hayase T. Radical scavenging mechanisms of MCI-186. Jpn Pharmacol Ther 1997; 25: 189-197.
12. Tada S, Nakamoto N, Kameyama K, Tsunematsu S, Kumagai N, Saito H, et al. Clinical usefulness of edaravone for acute liver injury. J Gastroenterol Hepatol 2003; 18: 851-857.
13. Yuan Z, Kishimoto C, Sano H, Shioji K, Xu Y, Yokode M. Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein Edeficient mice via the Fc portion. Am J Physiol 2003; 285: H899-H906.
14. Okabe T, Kishimoto C, Shimada K, Murayama T, Yokode M, Kita T. Effects of immunoglobulin administration on experimental atherosclerosis in apolipoprotein E-deficient mice at subsequent stage. Circ J 2005; 69: 1543-1546.
15. Murayama T, Yokode M, Kataoka H, Imabayashi T, Yoshida H, Sano H, et al. Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but dose not reduce the size of advanced lesions in apolipoprotein E-deficient mice. Circulation 1999; 99: 1740-1746.
16. Nicoletti A, Kaveri S, Caligiuri G, Bariéty J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998; 102: 910-918.
17. Shioji K, Kishimoto C, Nakamura H, Toyokuni S, Nakayama Y, Yodoi J, et al. Upregulation of thioredoxin (TRX) expression in giant cell myocarditis in rats. FEBS Lett 2000; 472: 109-113.
18. Yuan Z, Kishimoto C, Shioji K, Nakamura H, Yodoi J, Sasayama S. Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression. Cardiovasc Res 2002; 55: 320-328.
19. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, et al. Overexpression of thioredoxin in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 2002; 106: 1403-1409.
20. Matsue H, Edelbaum D, Shalhevet D, Mizumoto N, Yang C, Mummert ME, et al. Generation and function of reactive oxygen species in dendritic cells during antigen presentation. J Immunol 2003; 171: 3010-3018.
21. Shioji K, Kishimoto C, Sasayama S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: Concomitant suppression of the expression of dendritic cells. Circ Res 2001; 89: 540-546.
22. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-486.
23. Mineo C, Gormley AK, Yuhanna IS, Osborne-Lawrence S, Gibson LL, Hahner L, et al. FcRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res 2005; 112: 1016-1023.
24. Nimata M, Okabe T, Hattori M, Yuan Z, Shioji K, Kishimoto C. MCI-186 (edaravone), a novel free radical scavenger, protects against acute autoimmune myocarditis in rats. Am J Physiol 2005; 289: H2514-H2518.